Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Top 3 dividend stocks to buy for 2026
Published: June 04, 2025 by: Finbold
Sentiment: Positive
Holding dividend stocks remains one of the most effective long-term strategies, with companies that pay a regular dividend often being profitable and well-positioned for future growth, even during economic downturns.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (June 2025)
Published: June 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Jeff J Mitchell / Getty Images News via Getty Images Pfizer (PFE) Price Prediction 2025–2030 The current consensus one-year price target for Pfizer, according to analysts, is $27.63, which represents 17.42% potential upside over the next 12 months based on PFE's current share price.
Read More
Pfizer's R&D Optimization Delivers Great Results & Secure Dividends
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Positive
PFE's meltdown has already triggered the richer forward dividend yields, made secure by the growing cash flow and the ongoing cost optimizations. The same has been observed in the FQ1'25 adj EPS outperformance, reiterated FY2025 guidance, and them "currently trending toward the upper end of the adjusted diluted EPS guidance range." While there is no avoiding the COVID-19 sales erosion and the upcoming patent cliff with ~$29B in revenues at stake, PFE has optimized its R&D efforts indeed.
Read More
Top 4 Value Stocks to Buy as Trade Tensions Still Cloud H2 Outlook
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
STNE, CNC, CVS and PFE stand out as top value picks amid trade tensions and a murky H2 economic outlook.
Read More
Buy, Sell, Or Hold PFE Stock At $23?
Published: June 03, 2025 by: Forbes
Sentiment: Negative
Pfizer (NYSE:PFE) stock is down around 25% from its 52-week high of over $31 to $23 now. Pipeline setbacks, including an experimental treatment for Duchenne muscular dystrophy (DMD) failing in a late-stage trial, and concerns about management's decisions on R&D spending and acquisitions have weighed on Pfizer's stock lately.
Read More
3 Low-Priced Dividend Stocks Paying Over 5% Right Now
Published: June 03, 2025 by: 24/7 Wall Street
Sentiment: Positive
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
Read More
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning t.
Read More
Put Cash To Work: 2 Magnificent Dividends I'm Betting On
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
High-quality assets like RTX and AbbVie are ideal for growth and income, offering inflation resilience and strong shareholder returns. RTX has a robust $217B backlog, rising global defense spending, robust margins, and a 32-year dividend growth streak, justifying its GARP valuation. AbbVie is rapidly replacing Humira revenue with high-growth drugs, maintains industry-leading margins, and delivers a 3.5% yield with double-digit EPS growth potential.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Are Investors Undervaluing Pfizer (PFE) Right Now?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and PSFE are some such stocks.
Read More
Collaborations for Change: AUA and Pfizer Select Recipients for $1.5 Million Grant Program to Improve Advanced Prostate Cancer Care
Published: May 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
BALTIMORE, May 29, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) is excited to announce it has selected seven grant winners to split $1.5 million as part of a collaborative initiative with Pfizer External Research & Grants (ER&G) which is aimed to improve the quality of care for individuals with advanced prostate cancer.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Published: May 26, 2025 by: Seeking Alpha
Sentiment: Positive
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immature, results from competitors such as Instil Bio are promising. We think Instil Bio, through its low valuation, and Pfizer, given its dividend yield, constitute good Buy opportunities to get exposure to the field.
Read More
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
Published: May 23, 2025 by: MarketBeat
Sentiment: Positive
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Read More
Astellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatment with XTANDI (enzalutamide) plus ADT was associated with a 66% probability of survival at five years compared to 53% probability of survival with placebo plus ADT XTANDI (enzalutamide) is the first and only androgen receptor inhibitor to demonstrate an overall survival benefit at five years in men with metastatic hormone-sensitive prostate cancer Data continue to show wide-ranging effect of treatment with XTANDI (enzalutamide) plus ADT across various patient subgroups, …
Read More
5 Low Price-to-Sales Stocks That Can Deliver Big Returns in 2025
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Neutral
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GDOT, JAKK, PCB, ROCK and PFE hold promise.
Read More
Pfizer Looks Like A Great Play At Current Valuations
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, while maintaining solid margins and forward growth expectations. Risks include increased competition in the ATTR-CM market and ongoing technical downtrends, but cost-cutting measures may enhance efficiency.
Read More
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea , May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal …
Read More
Pfizer Thinks Bigger With 3SBio Deal
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows increased control of its oncology pipeline and much higher financial rewards in the long run, and comes at a relatively low cost. The jury is still out on the PD-1/VEGF bispecific antibody class of drugs, but the data to date make this approach worth exploring, and perhaps even necessary.
Read More
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Published: May 20, 2025 by: Investopedia
Sentiment: Positive
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Read More
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
Read More
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Read More
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Read More
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.
Read More
High-Yield Dividend Portfolios Outperform: These Are Our 5 Favorite Stock Picks
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Published: May 18, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
Read More
Pfizer's Turnaround Story Is Stronger Than You Think
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000